184 related articles for article (PubMed ID: 21885619)
1. Indirect sympatholytic actions at β-adrenoceptors account for the ocular hypotensive actions of cannabinoid receptor agonists.
Hudson BD; Beazley M; Szczesniak AM; Straiker A; Kelly ME
J Pharmacol Exp Ther; 2011 Dec; 339(3):757-67. PubMed ID: 21885619
[TBL] [Abstract][Full Text] [Related]
2. Nonpsychotropic cannabinoids, abnormal cannabidiol and canabigerol-dimethyl heptyl, act at novel cannabinoid receptors to reduce intraocular pressure.
Szczesniak AM; Maor Y; Robertson H; Hung O; Kelly ME
J Ocul Pharmacol Ther; 2011 Oct; 27(5):427-35. PubMed ID: 21770780
[TBL] [Abstract][Full Text] [Related]
3. The cannabinoid agonist WIN 55,212-2 inhibits TNF-alpha-induced neutrophil transmigration across ECV304 cells.
Nilsson O; Fowler CJ; Jacobsson SO
Eur J Pharmacol; 2006 Oct; 547(1-3):165-73. PubMed ID: 16928371
[TBL] [Abstract][Full Text] [Related]
4. [Cannabinoid applications in glaucoma].
Pinar-Sueiro S; Rodríguez-Puertas R; Vecino E
Arch Soc Esp Oftalmol; 2011 Jan; 86(1):16-23. PubMed ID: 21414525
[TBL] [Abstract][Full Text] [Related]
5. Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor.
Fride E; Foox A; Rosenberg E; Faigenboim M; Cohen V; Barda L; Blau H; Mechoulam R
Eur J Pharmacol; 2003 Feb; 461(1):27-34. PubMed ID: 12568912
[TBL] [Abstract][Full Text] [Related]
6. Antitussive effect of WIN 55212-2, a cannabinoid receptor agonist.
Morita K; Kamei J
Eur J Pharmacol; 2003 Aug; 474(2-3):269-72. PubMed ID: 12921873
[TBL] [Abstract][Full Text] [Related]
7. The In Vivo Effects of the CB
Cairns EA; Szczesniak AM; Straiker AJ; Kulkarni PM; Pertwee RG; Thakur GA; Baldridge WH; Kelly MEM
J Ocul Pharmacol Ther; 2017 Oct; 33(8):582-590. PubMed ID: 28719234
[TBL] [Abstract][Full Text] [Related]
8. Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase.
Naidu PS; Kinsey SG; Guo TL; Cravatt BF; Lichtman AH
J Pharmacol Exp Ther; 2010 Jul; 334(1):182-90. PubMed ID: 20375198
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoids excite hypothalamic melanin-concentrating hormone but inhibit hypocretin/orexin neurons: implications for cannabinoid actions on food intake and cognitive arousal.
Huang H; Acuna-Goycolea C; Li Y; Cheng HM; Obrietan K; van den Pol AN
J Neurosci; 2007 May; 27(18):4870-81. PubMed ID: 17475795
[TBL] [Abstract][Full Text] [Related]
10. Evidence against cannabinoid receptor involvement in intraocular pressure effects of cannabinoids in rabbits.
Hodges LC; Reggio PH; Green K
Ophthalmic Res; 1997; 29(1):1-5. PubMed ID: 9112260
[TBL] [Abstract][Full Text] [Related]
11. R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor.
Sánchez AJ; González-Pérez P; Galve-Roperh I; García-Merino A
Biochem Pharmacol; 2006 Dec; 72(12):1697-706. PubMed ID: 17007821
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors.
Accorsi-Mendonça D; Almado CE; Dagostin AL; Machado BH; Leão RM
Brain Res; 2008 Mar; 1200():1-9. PubMed ID: 18308297
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation.
Marchalant Y; Rosi S; Wenk GL
Neuroscience; 2007 Feb; 144(4):1516-22. PubMed ID: 17178196
[TBL] [Abstract][Full Text] [Related]
14. Characterization of cannabinoid modulation of sensory neurotransmission in the rat isolated mesenteric arterial bed.
Duncan M; Kendall DA; Ralevic V
J Pharmacol Exp Ther; 2004 Oct; 311(1):411-9. PubMed ID: 15205450
[TBL] [Abstract][Full Text] [Related]
15. Cortical adrenoceptor expression, function and adaptation under conditions of cannabinoid receptor deletion.
Reyes BAS; Carvalho AF; Szot P; Kalamarides DJ; Wang Q; Kirby LG; Van Bockstaele EJ
Exp Neurol; 2017 Jun; 292():179-192. PubMed ID: 28341460
[TBL] [Abstract][Full Text] [Related]
16. N-methyl-D-aspartate antagonists and WIN 55212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1-i,j]quinolin-6-one], a cannabinoid agonist, interact to produce synergistic hypothermia.
Rawls SM; Cowan A; Tallarida RJ; Geller EB; Adler MW
J Pharmacol Exp Ther; 2002 Oct; 303(1):395-402. PubMed ID: 12235276
[TBL] [Abstract][Full Text] [Related]
17. Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: antinociception, drug discrimination, and drug self-administration.
Maguire DR; Yang W; France CP
J Pharmacol Exp Ther; 2013 Jun; 345(3):354-62. PubMed ID: 23536317
[TBL] [Abstract][Full Text] [Related]
18. Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: Study on electrophysiological and behavioral models of temporal lobe epilepsy in the rat.
Carletti F; Gambino G; Rizzo V; Ferraro G; Sardo P
Neuroscience; 2015 Sep; 303():149-59. PubMed ID: 26135674
[TBL] [Abstract][Full Text] [Related]
19. Induction of cannabinoid- and N-methyl-D-aspartate receptor-mediated long-term depression in the nucleus accumbens and dorsolateral striatum is region and age dependent.
Zhang X; Feng ZJ; Chergui K
Int J Neuropsychopharmacol; 2015 Jan; 18(4):. PubMed ID: 25618403
[TBL] [Abstract][Full Text] [Related]
20. Role of CB2 receptors and cGMP pathway on the cannabinoid-dependent antiepileptic effects in an in vivo model of partial epilepsy.
Rizzo V; Carletti F; Gambino G; Schiera G; Cannizzaro C; Ferraro G; Sardo P
Epilepsy Res; 2014 Dec; 108(10):1711-8. PubMed ID: 25458534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
